Javad Malakootikhah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Javad Malakootikhah has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Aghil Sharifzadeh
Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
3 shared publications - Ali Reza Khosravi
Department of Immunology and Microbiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
3 shared publications - Bahar Nayeri Fasaei
Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
2 shared publications - Donya Nikaein
Department of Microbiology and Immunology Faculty of Veterinary Medicine University of Tehran Tehran Iran
2 shared publications - Abolfazl Rafati Zomorodi
HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication Alaleh Vazifehdust
Faculty of Veterinary Medicine University of Tehran Tehran Iran
1 shared publication
Latest Publications
- 17 September 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (10) , 629
Antifungal Activity and Binding Potential of Nanoencapsulated Propolis Against Key Cell Wall and Plasma Membrane Biosynthetic Enzymes in Resistant Candida albicans
- 17 September 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (10) , 629
Antifungal Activity and Binding Potential of Nanoencapsulated Propolis Against Key Cell Wall and Plasma Membrane Biosynthetic Enzymes in Resistant Candida albicans
- Open Access
- 20 May 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (3) , e71001
Nano‐Encapsulated Cinnamomum cassia Essential Oil in Combination With Fluconazole Exhibits Synergistic Activity Against Fluconazole‐Resistant Nakaseomyces glabratus and Pichia kudriavzevii
Background: Nakaseomyces species, particularly Nakaseomyces glabratus and Pichia kudriavzevii , pose remarkable treatment challenges due to their resistance to common antifungal agents like fluconazole (FCZ). Essential oils, such as Cinnamomum cassia essential oil (CC‐EO), offer a promising alternative, especially when enhanced with nanotechnology to improve stability and bioavailability. Aim: This study aims to evaluate the antifungal efficacy of CC‐EO and its nano‐encapsulated form (nano‐CC‐EO) against Nakaseomyces spp. to explore their potential as alternative treatments for resistant candidiasis. Methods: Ten clinical isolates of N. glabratus and P. kudriavzevii were tested using CC‐EO and nano‐CC‐EO, which were prepared via nanoprecipitation. Antifungal efficacy was evaluated through disk diffusion, microdilution and checkerboard assays, whereas nano‐CC‐EO's physicochemical properties were characterized using dynamic light scattering, scanning electron microscopy and zeta potential analysis. Results: Characterization of nano‐CC‐EO showed an average particle size of 174.8 nm and a stable zeta potential of −18.6 mV, confirming uniformity and stability. In disk diffusion screening, nano‐CC‐EO produced larger inhibition zones than CC‐EO at 2000 ppm, providing a qualitative indication of stronger growth inhibition. Microdilution tests revealed minimum inhibitory concentration (MIC) values of 250–500 ppm for nano‐CC‐EO and 125–500 ppm for CC‐EO, highlighting strong inhibitory effects against Nakaseomyces isolates. Checkerboard assays demonstrated synergistic and additive interactions between nano‐CC‐EO and FCZ, with several isolates showing fractional inhibitory concentration index (FICI) values below 0.5. Conclusion: This study highlights the enhanced antifungal potential of nano‐CC‐EO, offering a promising alternative for treating resistant Nakaseomyces infections. Nano‐CC‐EO formulations demonstrated superior efficacy and targeted delivery, suggesting their potential as effective natural antifungal agents.
- 20 May 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (3) , e71001
Open AccessNano‐Encapsulated Cinnamomum cassia Essential Oil in Combination With Fluconazole Exhibits Synergistic Activity Against Fluconazole‐Resistant Nakaseomyces glabratus and Pichia kudriavzevii
Background: Nakaseomyces species, particularly Nakaseomyces glabratus and Pichia kudriavzevii , pose remarkable treatment challenges due to their resistance to common antifungal agents like fluconazole (FCZ). Essential oils, such as Cinnamomum cassia essential oil (CC‐EO), offer a promising alternative, especially when enhanced with nanotechnology to improve stability and bioavailability. Aim: This study aims to evaluate the antifungal efficacy of CC‐EO and its nano‐encapsulated form (nano‐CC‐EO) against Nakaseomyces spp. to explore their potential as alternative treatments for resistant candidiasis. Methods: Ten clinical isolates of N. glabratus and P. kudriavzevii were tested using CC‐EO and nano‐CC‐EO, which were prepared via nanoprecipitation. Antifungal efficacy was evaluated through disk diffusion, microdilution and checkerboard assays, whereas nano‐CC‐EO's physicochemical properties were characterized using dynamic light scattering, scanning electron microscopy and zeta potential analysis. Results: Characterization of nano‐CC‐EO showed an average particle size of 174.8 nm and a stable zeta potential of −18.6 mV, confirming uniformity and stability. In disk diffusion screening, nano‐CC‐EO produced larger inhibition zones than CC‐EO at 2000 ppm, providing a qualitative indication of stronger growth inhibition. Microdilution tests revealed minimum inhibitory concentration (MIC) values of 250–500 ppm for nano‐CC‐EO and 125–500 ppm for CC‐EO, highlighting strong inhibitory effects against Nakaseomyces isolates. Checkerboard assays demonstrated synergistic and additive interactions between nano‐CC‐EO and FCZ, with several isolates showing fractional inhibitory concentration index (FICI) values below 0.5. Conclusion: This study highlights the enhanced antifungal potential of nano‐CC‐EO, offering a promising alternative for treating resistant Nakaseomyces infections. Nano‐CC‐EO formulations demonstrated superior efficacy and targeted delivery, suggesting their potential as effective natural antifungal agents.
- Open Access
- 27 November 2025
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (1) , e70646
The Inhibitory Effects of Zinc Oxide Nanoparticles on Clinical Isolates of Malassezia in Dogs
Introduction: Malassezia pachydermatis is frequently detected among the microflora of endothermic vertebrates, acts opportunistically, and contributes to the development of dermatitis and otitis in humans and animals. Treating chronic or recurrent cases of external otitis can pose a challenge, and replacing common antibiotics and antifungal agents with nanoparticles can be crucial in mitigating drug resistance. The present study investigated zinc oxide (ZnO) nanoparticles' antifungal effects on Malassezia pachydermatis clinical isolates and Phospholipase A2 and Aspartyl proteinase gene expression. Materials and methods: Zinc oxide nanoparticles were prepared using the direct precipitation method at a concentration of 2000 ppm. Its antifungal potential was evaluated at concentrations of 1.95 to 2000 ppm by disk diffusion and micro‐dilution methods against ten isolates of Malassezia pachydermatis . The effect of this product on Phospholipase A2 and Aspartyl proteinase gene expression was investigated by Quantitative real‐time PCR method. Results: The results of the disk diffusion test showed that the highest inhibitory diameter was at the highest concentration of ZnO nanoparticles (23.9 mm), and the inhibitory zone was observed in dilutions up to 250 ppm. The minimum inhibitory concentration of ZnO nanoparticles was between 3.90 and 7.81 ppm, and the minimum fungicidal concentration was between 7.81 and 15.62 ppm. There was a significant reduction in Phospholipase A2 and Aspartyl proteinase gene expression in sub‐MIC concentration (1.95–3.90 ppm) ( p < 0.05). Conclusion: The present study provides evidence of the concentration‐dependent antifungal activity of ZnO nanoparticles on Malassezia pachydermatis and suggests that they may be a viable alternative to traditional antifungal agents. Further research is necessary to explore the safety and efficacy of these nanoparticles in vivo.
- 27 November 2025
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (1) , e70646
Open AccessThe Inhibitory Effects of Zinc Oxide Nanoparticles on Clinical Isolates of Malassezia in Dogs
Introduction: Malassezia pachydermatis is frequently detected among the microflora of endothermic vertebrates, acts opportunistically, and contributes to the development of dermatitis and otitis in humans and animals. Treating chronic or recurrent cases of external otitis can pose a challenge, and replacing common antibiotics and antifungal agents with nanoparticles can be crucial in mitigating drug resistance. The present study investigated zinc oxide (ZnO) nanoparticles' antifungal effects on Malassezia pachydermatis clinical isolates and Phospholipase A2 and Aspartyl proteinase gene expression. Materials and methods: Zinc oxide nanoparticles were prepared using the direct precipitation method at a concentration of 2000 ppm. Its antifungal potential was evaluated at concentrations of 1.95 to 2000 ppm by disk diffusion and micro‐dilution methods against ten isolates of Malassezia pachydermatis . The effect of this product on Phospholipase A2 and Aspartyl proteinase gene expression was investigated by Quantitative real‐time PCR method. Results: The results of the disk diffusion test showed that the highest inhibitory diameter was at the highest concentration of ZnO nanoparticles (23.9 mm), and the inhibitory zone was observed in dilutions up to 250 ppm. The minimum inhibitory concentration of ZnO nanoparticles was between 3.90 and 7.81 ppm, and the minimum fungicidal concentration was between 7.81 and 15.62 ppm. There was a significant reduction in Phospholipase A2 and Aspartyl proteinase gene expression in sub‐MIC concentration (1.95–3.90 ppm) ( p < 0.05). Conclusion: The present study provides evidence of the concentration‐dependent antifungal activity of ZnO nanoparticles on Malassezia pachydermatis and suggests that they may be a viable alternative to traditional antifungal agents. Further research is necessary to explore the safety and efficacy of these nanoparticles in vivo.
- Open Access
- 23 May 2025
- Published by Wiley in Veterinary Medicine and Science
- Vol. 11 (3) , e70407
Evaluating the Antimicrobial and Antibiofilm Efficacy of Lavender Essential Oil and Linalool on Dual Candida albicans Biofilms With Staphylococcus aureus and Staphylococcus epidermidis From Canine External Otitis
Background: Biofilm formation significantly contributes to the rise of antimicrobial resistance, treatment failures and recurrent infections. Essential oils (EOs), particularly lavender EO (LEO), have gained attention for their antimicrobial and antibiofilm activities. This study investigates the effects of LEO and linalool on Staphylococcus aureus ( S. aureus ), Staphylococcus epidermidis ( S. epidermidis ), and Candida albicans ( C. albicans ) isolates. Materials and Methods: The chemical composition of LEO was analysed using gas chromatography‐mass spectrometry (GC‐MS). Eight clinical and reference microorganisms were tested, including four C. albicans , three S. aureus , and three S. epidermidis isolates, to assess their biofilm‐producing potential with the tissue microtiter plate method. Antimicrobial and antibiofilm activities of LEO and linalool were evaluated in planktonic, single‐biofilm, and dual‐biofilm phases through microbroth dilution and scanning electron microscopy (SEM). Results: The minimum inhibitory concentration (MIC) and minimum bactericidal/fungicidal concentration (MBC/MFC) of LEO in the planktonic phase were 1250 µg/mL and 2500 µg/mL against Staphylococcus isolates, respectively, while the corresponding value for C. albicans isolates was 5000 µg/mL. 90% biofilm inhibition was achieved at concentrations of 5000 µg/mL and 40,000 µg/mL for Staphylococcus and C. albicans , respectively. LEO completely inhibited dual biofilms formed by C. albicans / S. aureus and C. albicans / S. epidermidis at 20,000 µg/mL, whereas linalool attained 100% inhibition at 40,000 µg/mL. Conclusion: LEO demonstrates significant antimicrobial and antibiofilm activity against Staphylococcus and C. albicans isolates, effective in both planktonic and biofilm phases.
- 23 May 2025
- Published by Wiley in Veterinary Medicine and Science
- Vol. 11 (3) , e70407
Open AccessEvaluating the Antimicrobial and Antibiofilm Efficacy of Lavender Essential Oil and Linalool on Dual Candida albicans Biofilms With Staphylococcus aureus and Staphylococcus epidermidis From Canine External Otitis
Background: Biofilm formation significantly contributes to the rise of antimicrobial resistance, treatment failures and recurrent infections. Essential oils (EOs), particularly lavender EO (LEO), have gained attention for their antimicrobial and antibiofilm activities. This study investigates the effects of LEO and linalool on Staphylococcus aureus ( S. aureus ), Staphylococcus epidermidis ( S. epidermidis ), and Candida albicans ( C. albicans ) isolates. Materials and Methods: The chemical composition of LEO was analysed using gas chromatography‐mass spectrometry (GC‐MS). Eight clinical and reference microorganisms were tested, including four C. albicans , three S. aureus , and three S. epidermidis isolates, to assess their biofilm‐producing potential with the tissue microtiter plate method. Antimicrobial and antibiofilm activities of LEO and linalool were evaluated in planktonic, single‐biofilm, and dual‐biofilm phases through microbroth dilution and scanning electron microscopy (SEM). Results: The minimum inhibitory concentration (MIC) and minimum bactericidal/fungicidal concentration (MBC/MFC) of LEO in the planktonic phase were 1250 µg/mL and 2500 µg/mL against Staphylococcus isolates, respectively, while the corresponding value for C. albicans isolates was 5000 µg/mL. 90% biofilm inhibition was achieved at concentrations of 5000 µg/mL and 40,000 µg/mL for Staphylococcus and C. albicans , respectively. LEO completely inhibited dual biofilms formed by C. albicans / S. aureus and C. albicans / S. epidermidis at 20,000 µg/mL, whereas linalool attained 100% inhibition at 40,000 µg/mL. Conclusion: LEO demonstrates significant antimicrobial and antibiofilm activity against Staphylococcus and C. albicans isolates, effective in both planktonic and biofilm phases.
- Open Access
- 5 May 2025
- Published by Wiley in Veterinary Medicine and Science
- Vol. 11 (3) , e70352
Synergistic Antifungal Efficacy of Eugenol‐Loaded Nanocapsules Combined With Itraconazole Against Trichophyton mentagrophytes
Background and Objectives: The increasing prevalence of dermatophyte infections and the emergence of antifungal resistance highlight the urgent need for novel treatment approaches. Trichophyton mentagrophytes , a common dermatophyte, often resists standard antifungal therapies, necessitating alternative solutions. Eugenol, a natural compound with potent antifungal properties, has gained attention for its synergistic effects with conventional antifungal agents. However, its clinical application is limited by poor bioavailability and stability. Nanoencapsulation of eugenol offers a promising strategy to enhance its antifungal efficacy and address these limitations. This study aims to evaluate the antifungal efficacy of eugenol and nanoencapsulated eugenol in combination with Itraconazole against T. mentagrophytes isolates. Methods: Eugenol‐loaded nanocapsules were fabricated using the nanoprecipitation method and subsequently evaluated. The antifungal activity of eugenol, nano‐eugenol and Itraconazole—individually and in combination—was assessed against clinical isolates of T. mentagrophytes derived from animal and human sources, using minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) determinations. The chequerboard assay evaluated the synergistic effects. Results: Scanning electron microscopy (SEM) and dynamic light scattering (DLS) analyses showed that eugenol nanocapsules have a uniform, spherical morphology with an average size of 150.9 nm and moderate polydispersity (polydispersity index [PDI] = 0.531), whereas a slight negative zeta potential (−0.1 mV) contributes to suspension stability by minimizing aggregation. The geometric mean MIC of eugenol was 119.3 µg/mL, significantly lower than that of nano‐eugenol (477.4 µg/mL), whereas Itraconazole had the lowest MIC at 11 µg/mL. Eugenol demonstrated a more potent fungicidal effect than its nanoencapsulated form, though nanoencapsulation improved stability and bioavailability. Combining Itraconazole with nano‐eugenol showed synergy in 73.3% of T. mentagrophytes isolates, reducing Itraconazole's MIC by up to 1/2 or 1/4. Both forms of eugenol exhibited effective anti‐dermatophytic activity. Conclusion: The findings suggest that nanoencapsulated eugenol, in combination with Itraconazole, provides a potent and synergistic antifungal approach against T. mentagrophytes , potentially reducing the dosage and resistance risks associated with Itraconazole. These results underscore the potential of nano‐enhanced plant extracts in developing effective, sustainable antifungal therapies.
- 5 May 2025
- Published by Wiley in Veterinary Medicine and Science
- Vol. 11 (3) , e70352
Open AccessSynergistic Antifungal Efficacy of Eugenol‐Loaded Nanocapsules Combined With Itraconazole Against Trichophyton mentagrophytes
Background and Objectives: The increasing prevalence of dermatophyte infections and the emergence of antifungal resistance highlight the urgent need for novel treatment approaches. Trichophyton mentagrophytes , a common dermatophyte, often resists standard antifungal therapies, necessitating alternative solutions. Eugenol, a natural compound with potent antifungal properties, has gained attention for its synergistic effects with conventional antifungal agents. However, its clinical application is limited by poor bioavailability and stability. Nanoencapsulation of eugenol offers a promising strategy to enhance its antifungal efficacy and address these limitations. This study aims to evaluate the antifungal efficacy of eugenol and nanoencapsulated eugenol in combination with Itraconazole against T. mentagrophytes isolates. Methods: Eugenol‐loaded nanocapsules were fabricated using the nanoprecipitation method and subsequently evaluated. The antifungal activity of eugenol, nano‐eugenol and Itraconazole—individually and in combination—was assessed against clinical isolates of T. mentagrophytes derived from animal and human sources, using minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) determinations. The chequerboard assay evaluated the synergistic effects. Results: Scanning electron microscopy (SEM) and dynamic light scattering (DLS) analyses showed that eugenol nanocapsules have a uniform, spherical morphology with an average size of 150.9 nm and moderate polydispersity (polydispersity index [PDI] = 0.531), whereas a slight negative zeta potential (−0.1 mV) contributes to suspension stability by minimizing aggregation. The geometric mean MIC of eugenol was 119.3 µg/mL, significantly lower than that of nano‐eugenol (477.4 µg/mL), whereas Itraconazole had the lowest MIC at 11 µg/mL. Eugenol demonstrated a more potent fungicidal effect than its nanoencapsulated form, though nanoencapsulation improved stability and bioavailability. Combining Itraconazole with nano‐eugenol showed synergy in 73.3% of T. mentagrophytes isolates, reducing Itraconazole's MIC by up to 1/2 or 1/4. Both forms of eugenol exhibited effective anti‐dermatophytic activity. Conclusion: The findings suggest that nanoencapsulated eugenol, in combination with Itraconazole, provides a potent and synergistic antifungal approach against T. mentagrophytes , potentially reducing the dosage and resistance risks associated with Itraconazole. These results underscore the potential of nano‐enhanced plant extracts in developing effective, sustainable antifungal therapies.
- Open Access
- 1 December 2023
- Published by Apex Publishing in Journal of Medicinal Plants
- Vol. 22 (87) , 1-25
Herbal nano-formulations in lung cancer: Superiorities to original forms
Background: LC (Lung cancer) is the most common type of cancer and has an increased mortality and morbidity rate throughout the world. Although radiation therapy, chemotherapy, and surgical approaches are among the common curative strategies against LC, these methods have not enough efficacies and may cause adverse effects. As a result, ...
- 1 December 2023
- Published by Apex Publishing in Journal of Medicinal Plants
- Vol. 22 (87) , 1-25
Open AccessHerbal nano-formulations in lung cancer: Superiorities to original forms
Background: LC (Lung cancer) is the most common type of cancer and has an increased mortality and morbidity rate throughout the world. Although radiation therapy, chemotherapy, and surgical approaches are among the common curative strategies against LC, these methods have not enough efficacies and may cause adverse effects. As a result, ...